Development and Manufacturing Challenges for Biologics - MaRS Future of Medicine Series
Wednesday, February 13, 2013 from 12:00 PM to 1:00 PM (EST)
Development and Manufacturing Challenges for Biologics
Come learn about the stages of drug development from someone who has seen it all. As a Contract Developing and Manufacturing Organization (CDMO) with their own innovation pipeline, Therapure Biopharma has a unique perspective on growing a business in the life sciences industry. VP Drug Development & CSO David Bell will share his experiences in drug development at Therapure with lessons for researchers and entrepreneurs alike.
About the speaker:
David N. Bell, M.Sc., Ph.D. , Vice President, Drug Development and Chief Scientific Officer
David's primary responsibility at Therapure has been the development of a pipeline of new protein and cell culture based product candidates for the treatment of anemia, cancer and infectious diseases. He also leads the team offering development services for new product entries. Prior to joining the company in 1994, David was Group Leader of Cancer Biology at BioChem Therapeutic, Inc. and before this, Laboratory Director of the BioVentures Division of FAA in Worcester, Massachussetts, USA. He received his Ph.D. from the Department of Medicine of McGill University in 1988 and completed a postdoctoral fellowship at the McGill Cancer Centre.
Part of the MaRS Future of Medicine™ Series
When & Where
MaRS Discovery District
MaRS (www.marsdd.com) is a large scale, mission driven innovation centre located in Toronto and networked across Ontario, focused on building Canada’s next generation of technology companies.
MaRS works closely with entrepreneurs to grow and scale their ventures into global market leaders in life sciences and health care, information, communications and entertainment technologies, cleantech, advanced materials and engineering, as well as innovative social purpose businesses.